Page 6,210«..1020..6,2096,2106,2116,212..6,2206,230..»

Donated stem cells may work best for heart patients

Posted: Published on November 7th, 2012

Stem cells culled from the bone marrow of healthy donors work as well or even better as cells harvested from patients themselves as a treatment for damaged hearts and are more convenient to use, according to new research. The 13-month trial was the first to compare the safety and effectiveness of so-called mesenchymal, or bone marrow-derived, stem cells taken from patients themselves versus those provided by donors. Such adult stem cells that renew themselves and mature into specific cell types have been used for 40 years in bone marrow transplants. Scientists are now exploring their use as treatments for ailments such as heart disease and inflammatory conditions, some of the biggest markets in medicine. The rationale behind using patients' own stem cells to treat disease is that they do not trigger an attack by the body's immune system. Mesenchymal stem cells, however, are also not recognized as foreign tissue. Researchers from the University of Miami Miller School of Medicine, funded by the National Institutes of Health, found that previously prepared cells from a healthy donor were comparatively safe and may offer the most convenience since it takes up to eight weeks to grow the amount of stem cells needed for … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Donated stem cells may work best for heart patients

Advocates, Patients Rally To Support Sarepta Early Drug Approval Push

Posted: Published on November 7th, 2012

BOSTON (TheStreet) -- Duchenne muscular dystrophy (DMD) advocacy groups are mobilizing to support efforts by Sarepta Therapeutics (SRPT) to seek accelerated approval for its experimental drug eteplirsen. Some of these groups, accompanied by parents of DMD patients, have already met with U.S. Food and Drug Administration officials to make sure regulators understand the urgent need for new therapies. More meetings with U.S. regulators are planned. Sarepta will meet with the FDA, likely early next year, to present results from the eteplirsen phase IIb study and request permission to file for accelerated approval. The company is holding a conference call Wednesday in conjunction with third-quarter financial results. See if (SRPT) is in our portfolio "We are absolutely going to do everything we can to get eteplirsen approved," said Sharon Hesterlee, senior director of research at Parent Project Muscular Dystrophy (PPMD), the largest DMD non-profit in the U.S. Originally posted here: Advocates, Patients Rally To Support Sarepta Early Drug Approval Push … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Advocates, Patients Rally To Support Sarepta Early Drug Approval Push

Autism treatment in homeopathy – Tv9 – Video

Posted: Published on November 7th, 2012

Autism treatment in homeopathy - Tv9 Autism treatment in homeopathy For more content go to http://www.freetv9.com Follow us on facebook at http Follow us on twitter at twitter.comFrom:tv9teluguViews:0 0ratingsTime:24:49More inNews Politics Read more here: Autism treatment in homeopathy - Tv9 - Video … Continue reading

Comments Off on Autism treatment in homeopathy – Tv9 – Video

Early intervention works in autism

Posted: Published on November 7th, 2012

Washington, November 7 (ANI): Children with autism spectrum disorders (ASD), who are given early treatment, made significant improvements in behaviour, communication, and most strikingly, brain function, a new study by Yale School of Medicine researchers has found. The results suggest that brain systems supporting social perception respond well to an early intervention behavioural program called pivotal response treatment. This treatment includes parent training, and employs play in its methods. ASDs are complex neurobiological disorders that inhibit a person's ability to communicate and develop social relationships, and are often accompanied by behavioural challenges. Until recently, autism diagnosis typically did not occur until a child was about three to five-years-old, and treatment programs were geared for this older age group. Yale Child Study Center researchers Fred Volkmar, M.D., Kevin A. Pelphrey, and their colleagues are diagnosing children as young as age one. Pivotal response treatment, developed at the University of California-Santa Barbara, combines developmental aspects of learning and development, and is easy to implement in children younger than age two. In the current study, the team used functional magnetic resonance imageing - for the first time - to measure changes in brain activity after two five-year-olds with ASD received pivotal response treatment. … Continue reading

Comments Off on Early intervention works in autism

Early treatment sparks striking brain changes in autism

Posted: Published on November 7th, 2012

ScienceDaily (Nov. 6, 2012) When given early treatment, children with autism spectrum disorders (ASD) made significant improvements in behavior, communication, and most strikingly, brain function, Yale School of Medicine researchers report in a new study. The study was published in the current issue of the Journal of Autism and Developmental Disorders by Yale Child Study Center researchers Dr. Fred Volkmar, Kevin A. Pelphrey, and their colleagues. The results suggest that brain systems supporting social perception respond well to an early intervention behavioral program called pivotal response treatment. This treatment includes parent training, and employs play in its methods. ASDs are complex neurobiological disorders that inhibit a person's ability to communicate and develop social relationships, and are often accompanied by behavioral challenges. Until recently, autism diagnosis typically did not occur until a child was about three- to five-years-old, and treatment programs were geared for this older age group. Today, Volkmar and his team are diagnosing children as young as age one. Pivotal response treatment, developed at the University of California-Santa Barbara, combines developmental aspects of learning and development, and is easy to implement in children younger than age two. In the current study, the team used functional magnetic resonance imaging -- … Continue reading

Comments Off on Early treatment sparks striking brain changes in autism

MedRecallNews.com Consumer Advocates, Philadelphia, PA

Posted: Published on November 7th, 2012

Philadelphia, PA (PRWEB) November 07, 2012 Beware of the dialysis danger zone! A popular dialysis treatment has been found to be responsible for an increased risk of sudden death from stroke and cardiac arrest. Med Recall News, the leading free Internet source on defective prescription medication and medical devices, has issued an official consumer alert today and posted free information about the dialysis treatment risk on its website. The United States Food and Drug Administration actually issued the most serious class one recall alert for a very common dialysis treatment, said Jesse Levine with MedRecall News. It caused so many health problems that they actually required the treatment to be pulled from the market. The common dialysis medication GranuFlo was found to increase bicarbonate levels in the blood, causing a condition called alkalosis. According to the FDA, alkalosis is responsible for the advanced risk of cardiac problems for users of the popular dialysis drug. In 2011, Fresenius Medical Care (FMC) issued an internal notice to its company-owned clinics, warning of the risks and side effects of GranuFlo. However; they failed to issue warnings to thousands of physicians and clinics not owned by FMC who continued to use their product. Dialysis … Continue reading

Comments Off on MedRecallNews.com Consumer Advocates, Philadelphia, PA

Home blood pressure monitoring may not benefit patients with stroke and hypertension

Posted: Published on November 7th, 2012

ScienceDaily (Nov. 5, 2012) Home blood pressure monitoring may help patients with hypertension and stroke but did not improve blood pressure control for patients who had normal blood pressure at the start or those with disabilities, according to a randomized controlled trial published in CMAJ (Canadian Medical Association Journal). "Overall, home monitoring did not improve blood pressure control in an unselected group of patients with hypertension and a history of stroke. However, it was associated with more changes in antihypertensive treatment during the trial, which suggested more active management in the intervention group," writes Sally Kerry, Centre for Primary Care and Public Health, Queen Mary, University of London, UK, with coauthors. Good blood pressure control can significantly reduce the risk of recurrent stroke in the estimated 15 million people who have strokes each year worldwide. Studies show that home monitoring is associated with lower blood pressure. The study involved 381 participants aged 30 (mean 72) years from three stroke units in London, UK, who were assigned to home monitoring or to a control group of usual care. Participants in the monitoring group were given a blood pressure monitor, brief training and telephone support from a nurse. The trial, including follow … Continue reading

Comments Off on Home blood pressure monitoring may not benefit patients with stroke and hypertension

Neurologists Remain Skeptical About the Launch Potential of Novel Pharmacotherapies in Clinical-Stage Development for …

Posted: Published on November 7th, 2012

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the worlds leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in light of repeated clinical trial failures of investigational treatments, neurologists remain skeptical about the launch potential of pharmacotherapies in clinical-stage development for the acute or post-acute treatment of ischemic stroke. As a result, Decision Resources expects that the market for ischemic stroke therapies will continue to be a graveyard for new product development in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. According to the Pharmacor advisory service entitled Acute Ischemic Stroke, interviewed neurologists continue to express uncertainty about the probability of success for Lundbecks thrombolytic desmoteplasecurrently the only novel drug in Phase III developmentin its redesigned pivotal clinical trial program. Although Decision Resources does not currently forecast approval of desmoteplase, its approval for use within three-to-nine hours post-stroke onset could represent one of the most important therapeutic achievements in stroke in more than a decade, while expanding the proportion of ischemic stroke patients with access to acute therapy. The findings also reveal that most interviewed experts convey limited optimism that neuroprotectants will prove effective in the treatment of ischemic stroke, given countless failures … Continue reading

Comments Off on Neurologists Remain Skeptical About the Launch Potential of Novel Pharmacotherapies in Clinical-Stage Development for …

Illinois senator vows January return to Washington after stroke

Posted: Published on November 7th, 2012

CHICAGO (Reuters) - Republican Senator Mark Kirk, who suffered a stroke last year, hopes to return to Washington in January, his spokesman said on Monday. Kirk, 53, won President Barack Obama's former seat in the U.S. Senate in 2010. He is not up for election this year. Kirk first made the comments on Sunday to a Chicago TV station at a fund-raiser for the clinic where he is receiving out-patient treatment. The event was Kirk's first public appearance since he suffered a stroke last January. According to the local NBC affiliate, Kirk, 53, told its reporter covering the stair-climbing fund-raiser that his next goal was to climb the stairs of Capitol Hill when the new Senate convenes in January. The station did not air nor post a clip of Kirk making the comments. But Erin Athas, Kirk's press secretary, confirmed to Reuters on Monday that his boss "was hoping to return in January." Kirk, who beat former Illinois Treasurer Alexi Giannoulias to win Obama's Senate seat in 2010, is one of two Illinois lawmakers sent to Washington who have been sidelined by illness this year. U.S. Representative Jesse Jackson Jr., a Democrat, has been on medical leave from the House … Continue reading

Comments Off on Illinois senator vows January return to Washington after stroke

Two feet, 500km and no sleep for charity

Posted: Published on November 7th, 2012

By Dan Satherley Her kids think she's "a bit nuts", and her mother wasn't impressed when she found out what her daughter was planning. But 47-year-old Kim Allan is adamant she is going to walk 500km nonstop, and without sleep. Why? To raise money and awareness for spinal cord injury research and treatment and because it's a challenge. On Thursday, November 22, Ms Allen will begin the first of 332 laps around the Sri Chinmoy Peace Mile at Auckland Domain, raising money for the Auckland Spinal Rehabilitation Unit in Otara and the Catwalk Spinal Cord Injury Trust. If she completes the full 500km, the next time the Tuakau mother-of-four gets to sleep, it will probably be Sunday. "It was a matter of finding something I could do that didn't involve a huge cost from me, or myself having to get sponsorship to cover the costs, because obviously that sponsorship could have gone towards fundraising," says Ms Allen, who currently makes a living off her art. Inspired by US ultra-runner Pam Reed, she decided running or walking fit the bill nicely. "I came up with the idea after reading Pam Reed's book," says Ms Allen. "I was looking at different options … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Two feet, 500km and no sleep for charity

Page 6,210«..1020..6,2096,2106,2116,212..6,2206,230..»